Suchergebnisse - "Kazandjian, Dickran"

PubPharm (8)

1

Daratumumab : A review of current indications and future directions

enthalten in: Seminars in oncology | 2022

von Hill, E. | Morrison, C. | Kazandjian, D.

2

Current and prospective antibody-based therapies in multiple myeloma

enthalten in: Seminars in oncology | 2022

von Bryer, E. | DeStefano, C. | Kazandjian, D.

3

A new era of novel immunotherapies for multiple myeloma

enthalten in: Lancet (London, England) | 2021

von Kazandjian, D. | Landgren, O.

4

The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!

enthalten in: Best practice & research. Clinical haematology | 2020

von Kazandjian, D. | Dew, A. | Hill, E.

5

A look backward and forward in the regulatory and treatment history of multiple myeloma : Approval of novel-novel agents, new drug development, and longer patient survival

enthalten in: Seminars in oncology | 2016

von Kazandjian, D. | Landgren, O.

6

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Carlsten, M. | Korde, N. | Kotecha, R. | +5

7

FDA Approval Summary : Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

enthalten in: The oncologist | 2016

von Kazandjian, D. | Suzman, D. | Blumenthal, G. | +5

CommentIn: Oncologist. 2016 Dec;21(12 ):e3. - PMID 27864576

8

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy : A Report From the US Food and Drug Administration

enthalten in: JAMA oncology | 2016

von Kazandjian, D. | Khozin, S. | Blumenthal, G. | +7

CommentIn: JAMA Oncol. 2016 Jan;2(1):122. - PMID 26468768

1
[1]